Glaxosmithkline Share News (GSK)
GSK Share
GSK Share
GSK Share
GSK Share
GSK
GSK Share
GSK Level 2
GSK Live
GSK Broker
GSK Directors
GSK Financial
GSK
GSK Short
GSK
Last checked at -
Dec 20 (Reuters) - Amicus Therapeutics Inc lost nearly half of its market value after the company said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study. The company's shares were down 43 percent at $3.28 in early trading on Thursday on the
20 Dec 12 15:47The continued haggling with Saudi Arabia over the price of 48 Eurofighter Typhoon jets could hit full-year profits at BAE Systems. The British defence contractor said that negotiations with the Royal Saudi Air Force about the price of the aircraft may not be concluded before its results announcement
20 Dec 12 06:51Dec 19 (Reuters) - Amicus Therapeutics said its experimental drug to treat a rare, inherited disorder failed to meet the main goal of a late-stage study, sending its shares down 50 percent in extended trade on Wednesday. The company is developing migalastat HCl in partnership with British drugmaker
19 Dec 12 22:48(Adds details, analyst quote) By Shida Chayesteh COPENHAGEN, Dec 19 (Reuters) - As Danish group Novo Nordisk awaits final approvals for its new long-acting diabetes drug Tresiba, a Reuters poll found a wide range of forecasts for sales of a drug meant to challenge its biggest rivals. Tresiba's annu
19 Dec 12 18:17Dec 19 (Reuters) - British drugmaker GlaxoSmithKline Plc has reached a $150 million preliminary settlement with U.S. drug wholesalers who claimed the company improperly delayed entry to the market of generic alternatives to its nasal spray Flonase, according to court documents. The settlement was r
19 Dec 12 17:11* Stimuvax fails to improve survival of lung cancer patients * Effects seen in some patients but analysts sceptical * News is setback for therapeutic cancer vaccine field * Merck falls 3.3 pct, Oncothyreon down 70 pct in premarket (Adds analyst comments, latest shares) By Maria Sheahan and Ben Hir
19 Dec 12 12:17* Stimuvax fails to improve survival of lung cancer patients * Effects seen in some patients but analysts sceptical * News is setback for therapeutic cancer vaccine field * Merck falls 3.3 pct, Oncothyreon down 70 pct in premarket (Adds analyst comments, latest shares) By Maria Sheahan and Ben Hir
19 Dec 12 12:17* Stimuvax fails to improve survival of lung cancer patients * Effects seen in some patients but analysts sceptical * News is setback for therapeutic cancer vaccine field * Merck falls 3.3 pct, Oncothyreon down 70 pct in premarket (Adds analyst comments, latest shares) By Maria Sheahan and Ben Hir
19 Dec 12 12:17* Stimuvax fails to improve survival of lung cancer patients * Merck: saw "notable treatment effects" on some patients * Merck says to analyse more data in coming weeks * Merck shares fall 3.5 percent (Adds further details, background) FRANKFURT, Dec 19 (Reuters) - German drugmaker Merck KGaA's c
19 Dec 12 08:32* Stimuvax fails to improve survival of lung cancer patients * Merck: saw "notable treatment effects" on some patients * Merck says to analyse more data in coming weeks * Merck shares fall 3.5 percent (Adds further details, background) FRANKFURT, Dec 19 (Reuters) - German drugmaker Merck KGaA's c
19 Dec 12 08:32* Stimuvax fails to improve survival of lung cancer patients * Merck: saw "notable treatment effects" on some patients * Merck says to analyse more data in coming weeks * Merck shares fall 3.5 percent (Adds further details, background) FRANKFURT, Dec 19 (Reuters) - German drugmaker Merck KGaA's c
19 Dec 12 08:32* EU agency sees more new drug applications in 2013 * U.S. new drug approvals running at eight-year high * Encouraging signals for industry as patent losses peak By Ben Hirschler LONDON, Dec 18 (Reuters) - The number of new medicines approved or pending approval is on the rise on both sides of the A
18 Dec 12 17:20Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the US for UMEC/VI medicine, used to treat chronic obstructive pulmonary disease (COPD). UMEC/VI is an investigational once-daily LAMA/LABA combination medicine. It includes properties, umeclidi
18 Dec 12 12:05(The following statement was released by the rating agency) Dec 18 - Most global pharmaceutical firms will survive unscathed the spike in expiries of patented drugs this year known as the "patent cliff", says Standard & Poor's Ratings Services today in the report card: "Why Global Pharmaceutical Fir
18 Dec 12 10:27AMEC: Credit Suisse reduces target price from 1300p to 1250p reiterating an outperform rating. Anglo American: Barclays upgrades to equal-weight with a target price of 1970p. Ashtead Group: Barclays raises target price from 352p to 434p and reiterates an overweight rating. ASOS: HSBC raises targe
12 Dec 12 07:25
Last checked at